Pramlintide: A new tool in diabetes management.
The amylin analogue pramlintide acts in concert with insulin to regulate glucose metabolism. It reduces postprandial hyperglycemia by suppressing postprandial glucagon secretion, regulating gastric emptying, and reducing food intake. In clinical use, pramlintide reduces postprandial glycemic excursions and improves A(1c) without the weight gain and increased risk of hypoglycemia typically seen with intensification of diabetes therapy.
Want
Laura L
LL
Ratner
Robert E
RE
D000682:Amyloid / Q000008:administration & dosage / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000473:pathology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000473:pathology; D005746:Gastric Emptying / Q000187:drug effects; D005934:Glucagon / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D058228:Islet Amyloid Polypeptide; D008954:Models, Biological; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism
D000682:Amyloid; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D005934:Glucagon; C105254:pramlintide